Vaccins polyosidiques

Boutonnier, 2001, Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid, Infect. Immun., 69, 3488, 10.1128/IAI.69.5.3488-3493.2001 Chong, 1997, A strategy for rational design of fully synthetic glycopeptide conjugate vaccines, Infect. Immun., 65, 4918, 10.1128/IAI.65.12.4918-4925.1997 Cohen, 1997, Double-blind vaccine-controlled randomized efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults, Lancet, 349, 155, 10.1016/S0140-6736(96)06255-1 Dochez, 1917, The elaboration of specific soluble substances by pneumococcus during growth, J. Exp. Med., 26, 477, 10.1084/jem.26.4.477 Eskola, 2001, Polysaccharide-based pneumococcal vaccines in the prevention of acute otitis media, Vaccine, 19, S78, 10.1016/S0264-410X(00)00283-8 Fattom, 1996, Staphylococcal vaccines : a realistic dream, Ann. Med., 28, 43, 10.3109/07853899608999073 Francis, 1930, Cutaneous reactions in pneumonia. The development of anti-bodies following the intradermal injection of type specific polysaccharide, J. Exp. Med., 52, 573, 10.1084/jem.52.4.573 Goebel, 1931, Chemo-immunological studies on conjugated carbohydrate-proteins. IV. The synthesis of the p-aminobenzyl ether of the soluble specific substance of type III pneumococcus and its coupling with protein, J. Exp. Med., 54, 431, 10.1084/jem.54.3.431 Goldblatt, 2000, Conjugate vaccines, Clin. Exp. Immunol., 119, 1, 10.1046/j.1365-2249.2000.01109.x Gupta, 1998, Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers, Infect. Immun., 66, 3095, 10.1128/IAI.66.7.3095-3099.1998 Heidelberger, 1923, The soluble specific substance of pneumococcus, J. Exp. Med., 38, 73, 10.1084/jem.38.1.73 Jennings, 1994, Synthetic glycoconjugates as human vaccines, 325 Kossaczka, 1997, Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker, Infect. Immun., 65, 2088, 10.1128/IAI.65.6.2088-2093.1997 Kossaczka, 2000, Vibrio cholerae O139 conjugate vaccines : Synthesis and immunogenicity of V. cholelae O139 capsular polysaccharide conjugates with recombinant diphteria toxin mutant in mice, Infect. Immun., 68, 5037, 10.1128/IAI.68.9.5037-5043.2000 Kotloff, 1999, Global burden of Shigella infections : implications for vaccine development and implementation of control strategies, Bull. WHO, 77, 651 Landsteiner, 1947, 156 Lin, 2001, The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children, N. Engl. J. Med., 344, 1263, 10.1056/NEJM200104263441701 MacLennan, 2000, Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants, JAMA, 283, 2795, 10.1001/jama.283.21.2795 McKenney, 1999, Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen, Science, 284, 1523, 10.1126/science.284.5419.1523 Meloen, 2000, Mimotopes : realization of an unlikely concept, J. Mol. Recognit., 13, 352, 10.1002/1099-1352(200011/12)13:6<352::AID-JMR509>3.0.CO;2-C Mims, 2001, The encouter with the phagocytic cell and the microb's answers, 84 Moreau, 2000, Polysaccharide based vaccines for the prevention of pneumococcal infections, J. Carbohydr. Chem., 19, 419, 10.1080/07328300008544091 Paoletti, 2001, Potency of clinical group B streptococcal conjugate vaccine, Vaccine, 19, 2118, 10.1016/S0264-410X(00)00437-0 Passwell, 2001, Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel, Infect. Immun., 69, 1351, 10.1128/IAI.69.3.1351-1357.2001 Pozsgay, 2000, Oligosaccharide-protein conjugates as vaccine candidates against bacteria, 153, 10.1016/S0065-2318(01)56004-7 Robbins, 1992, Hypothesis for vaccine development : protective immunity to enteric diseases caused by nontyphoidal Salmonellae and Shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides, Clin. Infect. Dis., 15, 346, 10.1093/clinids/15.2.346 Robbins, 1984, Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi, J. Infect. Dis., 150, 436, 10.1093/infdis/150.3.436 Roberts, 1989, Bacterial capsules and interaction with complement and phagocytes, Biochem. Soc. Trans., 17, 462, 10.1042/bst0170462 Schneerson, 1980, Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates, J. Exp. Med., 152, 361, 10.1084/jem.152.2.361 Shinefield, 2002, Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis, N. Engl. J. Med., 346, 491, 10.1056/NEJMoa011297 Tai, 1997, Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and non-human primates, J. Infect. Dis., 175, 364, 10.1093/infdis/175.2.364 Watson, 1993, A brief history of the Pneumococcus in biomedical research : A panoply of scientific discovery, Clin. Infect. Dis., 17, 913, 10.1093/clinids/17.5.913 Wenger, 1997, Epidemiological impact of conjugate vaccines on invasive disease caused by Haemophilus influenzae type b, 489